Evidence map›Paper›PMID 37188697›Full record

ArticleNature communications2023

Prioritization of potential causative genes for schizophrenia in placenta.

Gianluca Ursini, Pasquale Di Carlo, Sreya Mukherjee, Qiang Chen, Shizhong Han, Jiyoung Kim, Maya Deyssenroth, Carmen J Marsit, Jia Chen, Ke Hao and 2 more

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
8.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Schizophrenia.Nature reviews. Disease primers · 2025
    Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Gianluca UrsiniLieber Institute for Brain Development, Johns Hopkins University Medical Campus, Baltimore, MD, USA. gianluca.ursini@libd.org.ORCID 0000-0002-4733-5196
Pasquale Di CarloLieber Institute for Brain Development, Johns Hopkins University Medical Campus, Baltimore, MD, USA.
Sreya MukherjeeLieber Institute for Brain Development, Johns Hopkins University Medical Campus, Baltimore, MD, USA.
Qiang ChenLieber Institute for Brain Development, Johns Hopkins University Medical Campus, Baltimore, MD, USA.
Shizhong HanLieber Institute for Brain Development, Johns Hopkins University Medical Campus, Baltimore, MD, USA.ORCID 0000-0002-5114-6742
Jiyoung KimLieber Institute for Brain Development, Johns Hopkins University Medical Campus, Baltimore, MD, USA.
Maya DeyssenrothDepartments of Environmental Medicine and Public Health, Icahn School of Public Health at Mount Sinai, New York, NY, USA.
Carmen J MarsitDepartments of Environmental Health and Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA.ORCID 0000-0003-4566-150X
Jia ChenDepartments of Environmental Medicine and Public Health, Icahn School of Public Health at Mount Sinai, New York, NY, USA.
Ke HaoDepartment of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID 0000-0002-1815-9197
Giovanna PunziLieber Institute for Brain Development, Johns Hopkins University Medical Campus, Baltimore, MD, USA.ORCID 0000-0001-7530-3880
Daniel R WeinbergerLieber Institute for Brain Development, Johns Hopkins University Medical Campus, Baltimore, MD, USA. drweinberger@libd.org.ORCID 0000-0003-2409-2969
Johns Hopkins University · USIcahn School of Medicine at Mount Sinai · USEmory University · US

Funding

Two-Spirit Films in Indigenous Cancer HealthP30CA016056 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI CANDACE S JOHNSON · 1985 to 2026
$116.6M
Pilot Project ProgramP30ES019776 · NIEHS · EMORY UNIVERSITY · PI William Michael Caudle · 2013 to 2026
$22.6M
Maternal SARS-CoV-2 infection, placenta biology, and neurodevelopmental outcomes in the offspringR01HD107140 · NICHD · LIEBER INSTITUTE, INC. · PI Gianluca Ursini · 2022 to 2026
$6.5M
Identification and Characterization of Asymmetrically-Expressed GenesR37MH060233 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI GESCHWIND, DANIEL H · 2006 to 2014
$5.3M
Epigenetic and Transcriptional Dysregulation in Autism Spectrum DisorderR01MH094714 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI GESCHWIND, DANIEL H · 2011 to 2015
$2.8M
Characterizing the functional genomic atlas of human placenta and unveiling the prenatal programming of early-life developmentR01HD108310 · NICHD · EMORY UNIVERSITY · PI Jia Chen, Carmen Joseph Marsit · 2023 to 2026
$2.8M
2/3 Integrative Genomic Analysis of Human Brain Development and AutismR01MH110927 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI GESCHWIND, DANIEL H · 2016 to 2019
$2.7M
Enriching the Rhode Island Child Health StudyU24ES028507 · NIEHS · EMORY UNIVERSITY · PI MARSIT, CARMEN JOSEPH, STROUD, LAURA R · 2023 to 2025
$1.0M
Genetic Influences on Human Cortical DevelopmentR00MH102357 · NIMH · UNIV OF NORTH CAROLINA CHAPEL HILL · PI STEIN, JASON LOUIS · 2016 to 2018
$747k
Placental Transcriptomics and Risk for SchizophreniaR21MH125108 · NIMH · LIEBER INSTITUTE, INC. · PI URSINI, GIANLUCA · 2021 to 2022
$498k
NCI NIH HHS P30 CA016056NICHD NIH HHS HHSN275200800003CNICHD NIH HHS HHSN275200800003INICHD NIH HHS HHSN275200800012CNICHD NIH HHS HHSN275200800013CNICHD NIH HHS HHSN275200800014CNICHD NIH HHS HHSN275200800028CNICHD NIH HHS HHSN275201000009CNICHD NIH HHS R01 HD107140NICHD NIH HHS R01 HD108310NIEHS NIH HHS P30 ES019776NIEHS NIH HHS U24 ES028507NIMH NIH HHS R00 MH102357NIMH NIH HHS R01 MH094714NIMH NIH HHS R01 MH110927NIMH NIH HHS R21 MH125108NIMH NIH HHS R37 MH060233
6 · The paper itself

Abstract

Our earlier work has shown that genomic risk for schizophrenia converges with early life complications in affecting risk for the disorder and sex-biased neurodevelopmental trajectories. Here, we identify specific genes and potential mechanisms that, in placenta, may mediate such outcomes. We performed TWAS in healthy term placentae (N = 147) to derive candidate placental causal genes that we confirmed with SMR; to search for placenta and schizophrenia-specific associations, we performed an analogous analysis in fetal brain (N = 166) and additional placenta TWAS for other disorders/traits. The analyses in the whole sample and stratifying by sex ultimately highlight 139 placenta and schizophrenia-specific risk genes, many being sex-biased; the candidate molecular mechanisms converge on the nutrient-sensing capabilities of placenta and trophoblast invasiveness. These genes also implicate the Coronavirus-pathogenesis pathway and showed increased expression in placentae from a small sample of SARS-CoV-2-positive pregnancies. Investigating placental risk genes for schizophrenia and candidate mechanisms may lead to opportunities for prevention that would not be suggested by study of the brain alone.

Indexed as

COVID-19SchizophreniaFemaleHumansPlacentaPregnancySARS-CoV-2Trophoblasts

Identifiers

PMID37188697
PMCPMC10185564
OpenAlexW4376642122

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.